Identification of New Antibodies Targeting Malignant Plasma Cells for Immunotherapy by Next-Generation Sequencing-Assisted Phage Display

• Published in: Frontiers in immunology Vol. 13; p. 908093
• Main Authors: Krohn, Steffen, Boje, Ammelie Svea, Gehlert, Carina Lynn, Lutz, Sebastian, Darzentas, Nikos, Knecht, Henrik, Herrmann, Dietrich, Brüggemann, Monika, Scheidig, Axel J, Weisel, Katja, Gramatzki, Martin, Peipp, Matthias, Klausz, Katja
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 17.06.2022
• Subjects: Animals; Bacteriophages; CD38; CHO Cells; Cricetinae; Cricetulus; High-Throughput Nucleotide Sequencing; ICAM-1/CD54; Immunoglobulin G; Immunologic Factors; Immunology; Immunotherapy; Leukocytes, Mononuclear; Mice; monoclonal antibody; multiple myeloma; Peptide Library; phage display; Plasma Cells; ICAM-1/CD54; next-generation sequencing – NGS; multiple myeloma; phage display; immunotherapy; CD38; cellular panning; monoclonal antibody
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2022.908093

To identify new antibodies for the treatment of plasma cell disorders including multiple myeloma (MM), a single-chain Fragment variable (scFv) antibody library was generated by immunizing mice with patient-derived malignant plasma cells. To enrich antibodies binding myeloma antigens, phage display with cellular panning was performed. After depleting the immune library with leukocytes of healthy donors, selection of antibodies was done with L-363 plasma cell line in two consecutive panning rounds. Monitoring the antibodies' enrichment throughout the panning by next-generation sequencing (NGS) identified several promising candidates. Initially, 41 unique scFv antibodies evolving from different B cell clones were selected. Nine of these antibodies strongly binding to myeloma cells and weakly binding to peripheral blood mononuclear cells (PBMC) were characterized. Using stably transfected Chinese hamster ovary cells expressing individual myeloma-associated antigens revealed that two antibodies bind CD38 and intercellular adhesion molecule-1 (ICAM-1), respectively, and 7 antibodies target yet unknown antigens. To evaluate the therapeutic potential of our new antibodies, in a first proof-of-concept study the CD38 binding scFv phage antibody was converted into a chimeric IgG1. Further analyses revealed that #5-CD38-IgG1 shared an overlapping epitope with daratumumab and isatuximab and had potent anti-myeloma activity comparable to the two clinically approved CD38 antibodies. These results indicate that by phage display and deep sequencing, new antibodies with therapeutic potential for MM immunotherapy can be identified.